TWiV 1030: Clinical update with Dr. Daniel Griffin

This Week in Virology

Vincent Racaniello

Vincent, Microbe, Medicine, Microbiology, Racaniello, Infection, Virus, Virology, Pathogen, Infectious, Twiv, Science & Medicine

4.8 • 2.2K Ratings

🗓️ 29 July 2023

⏱️ 33 minutes

🔗️ Recording | iTunes | RSS

🧾️ Download transcript

Summary

In his weekly clinical update, Dr. Griffin discusses the use of RSV vaccines in older adults: recommendations of the advisory committee on immunization practices, case report of leprosy in Central Florida, blood group A enhances SARS-CoV-2 infection, predicting COVID-19 incidence using wastewater surveillance data, a common allele of HLA associated with asymptomatic SARS-CoV-2 infection, prevalence of low-frequency, antiviral resistance variants in SARS-CoV-2 isolates in Ontario, Canada, viral resistance analyses from the Remdesivir phase 3 adaptive COVID-19 treatment trial-1, impact of Molnupiravir treatment on patient-reported COVID-19 symptoms in the phase 3 move-out trial, Molnupiravir for treatment of adults with mild or moderate COVID-19, delayed intubation associated with in-hospital mortality in patients with COVID-19 respiratory failure who fail heated and humified high flow nasal canula, relationship between azithromycin and cardiovascular outcomes in unvaccinated patients with COVID‐19 and preexisting cardiovascular disease, and the effects of COVID-19 on cognitive performance in a community-based cohort, clinical phenotypes and quality of life to define post-COVID-19 syndrome. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Use of RSV vaccines in older adults (CDC) Case report of leprosy in Central Florida (EID) Blood group A enhances SARS-CoV-2 infection (Blood) Predicting COVID-19 incidence using wastewater surveillance data (EID) Common allele of HLA associated with asymptomatic SARS-CoV-2 infection (Nature) Prevalence of low-frequency antiviral resistance variants in SARS-CoV-2 isolates (JAMA) Viral resistance analyses from the Remdesivir phase 3 treatment trial (JID) Impact of Molnupiravir treatment on patient-reported COVID-19 symptoms (CID) Molnupiravir for treatment of adults with mild or moderate COVID-19 (CMI) Delayed intubation associated with in-hospital mortality in patients with COVID-19 (BMC) Relationship between Azithromycin and cardiovascular outcomes in unvaccinated patients with COVID‐19 (JAHA) The effects of COVID-19 on cognitive performance in a community-based cohort (eClinical) Clinical phenotypes and quality of life to define post-COVID-19 syndrome (eClinical) Contribute to our FIMRC fundraiser at PWB Letters read on TWiV 1030 Dr. Griffin’s COVID treatment summary (pdf) Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]

Transcript

Click on a timestamp to play from that location

0:00.0	This week in virology, the podcast about viruses, the kind that make you sick.
0:10.4	From microbe TV, this is TWIV, this week in virology, episode 130 recorded on July 26, 2023.
0:21.7	I'm Vincent Rackinello and you're listening to the podcast, all about viruses. Joining me today from
0:28.0	New York, Daniel Griffin. Hello, everyone. So as you would say to Sarah, where are you anyway, Sarah?
0:37.6	So I am just south of Manhattan here. I'm on a boat. I'm not wearing a bow tie. It is quite hot.
0:45.2	So if my glasses ring glasses fog up, you know why? I'm not sure I'm quite in New York, but I can
0:51.3	see New York City, but jump right into it. The optimist thinks this is the best of all possible
0:59.6	worlds. The pessimist fears it is true. And that's by Oppenheimer. I don't know if people have
1:05.2	gotten a chance to see that movie yet. It's an interesting movie. I had to choose, you know,
1:11.2	was I going to watch Barbie or Oppenheimer, right? So what a choice.
1:15.8	Apparently, I must watch Barbie next. I hear Barbie is a little bit more uplifting.
1:22.7	All right, RSV, the MMWR use of respiratory sensational virus vaccines and older adults,
1:29.6	recommendations of the advisory committee on immunization practices, United States,
1:34.4	2023 just came out. As if they heard Vincent's question when we recorded last week,
1:41.4	as a reminder, May 2023, the FDA approved the first two vaccines for prevention of RSV
1:49.5	lower respiratory tract disease for use in adults, two for adults. So we have an option to
1:54.7	vaccinate, vaccinate, vaccinate. I like that aged. It sounds better. I've been
2:03.3	vaccinated. The two vaccines are the RSV pre-F3. That's a Rex V like RxV by GSK.
2:14.2	That's a one dose adjuvanted recombinant stabilized perfusion F protein vaccine and RSV pre-F
2:22.0	that's a brisbee by Pfizer. It's also a one dose recombinant stabilized pre-F vaccine.
2:29.9	Now, the advisory committee on immunization practices recommended sounds familiar to folks aged
2:36.1	60 or older may receive a single dose of the RSV vaccine using shared clinical decision making.
	...

Please login to see the full transcript.

Previous episode | Next episode

Disclaimer: The podcast and artwork embedded on this page are from Vincent Racaniello, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of Vincent Racaniello and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.